Nektar Therapeutics (NKTR) Soared To A New High On Phase 3 Study Results

Nektar Therapeutics (NKTR) announced Monday morning that its Phase 3 efficacy study of NKTR-181 met the primary efficacy endpoint, demonstrating significantly improved chronic back pain relief. Key secondary endpoints of the study were also met with high statistical significance.

from RTT - Before the Bell http://ift.tt/2moeZYv
via IFTTT